Alpha Tau Medical

Historical price data

Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an intratumoral radiotherapy platform that uses Radium-224 impregnated sources to release short-lived, high-energy alpha particles that diffuse locally within the tumor, delivering a potent and conformal radiation dose while sparing healthy tissue.

Alpha Tau competes in the radiopharmaceutical space but is differentiated by its intratumoral, alpha-particle approach. Key competitors include providers of external beam radiotherapy, systemic radiopharmaceuticals (e.g., Novartis), and beta-brachytherapy. Its main advantages are the extreme potency and precise localization of alpha radiation.